In an effort to better understand diseases that have long eluded diagnosis, the New York Stem Cell Foundation Research Institute is partnering with the National Institutes of Health's Undiagnosed Diseases Program to create cell models of rare medical conditions.
China is a big, climatologically-diverse country, with the weather changing significantly between the temperate zones in the north and the subtropical regions further south. This affects when flu seasons occur, and consequently when health authorities should run vaccination campaigns.
Agenus and a Sanofi-NIH collaboration both gave updates on their genital herpes vaccine candidates this week. The Agenus vaccine, HerpV, is leading the race, having met its primary endpoint in a Phase II trial of 80 subjects, 70 of whom received the treatment.
The White House's Office of Management and Budget released a new report that sheds light on how the 16-day federal government shutdown in October impacted scientific research.
NIH has issued an updated fact sheet on the impact of federal sequestration, which totaled nearly $1.6 billion in cuts this year.
Over the past 12 months spending cuts at National Institutes of Health have raised doubts about its ability to continue increasing investment in next-generation sequencing at the rate seen in recent years. Yet this week brought two pieces of news that suggest NIH is backing more and more NGS projects.
Having updated its disease-modeling platform last week, tech giant IBM has now snagged a grant to dig into electronic health records to predict heart disease and opened a Big Data research lab.
When NIH canned its HIV vaccine trial in April, the field, yet again, lost its brightest hope. Since then, NIH has continued to monitor participants in the trial, and this week it presented an update in the New England Journal of Medicine.
Thanks to the government shutdown, about 73% of NIH staff have seen their jobs put on hold--and no staff means no new studies. As The Washington Post reports, the halt has forced researchers to turn away patients, as the NIH usually enrolls about 200 patients per week in clinical trials of experimental drugs.
The National Institutes of Health normally enrolls about 200 patients a week in ongoing trials of experimental therapies. Now, with about 73% of NIH staff sitting at home, the agency can't begin any new studies, forcing researchers to turn patients away.